Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:16 PM ET 10-Q
Financial Results XTI Aerospace, Inc. XTIA

XTI Aerospace Q3 2026 Results: Turns Profitable, Net Income $26M

XTI Aerospace reported total assets of $69.9 million as of September 30, 2026, a decrease from $81.2 million at year-end 2025, primarily driven by a reduction in cash and the disposal of its discontinued Inpixon Business. The company's balance sheet reflects significant liabilities including a $24.5 million warrant liability and the introduction of a $5.9 million asset-based revolving line of credit.

Key figure
Net income $26M
4:16 PM ET 8-K
Financial Results Flowers Foods Inc FLO

Flowers Foods Financial Results

Flowers Foods reported third quarter 2026 net sales of $1.169 billion, a 4.7% decrease year-over-year as favorable pricing was offset by lower volumes. Net income fell 63.6% to $14.4 million due to higher logistics costs and marketing investments, leading the company to lower its full-year 2026 financial guidance.

Term
12 weeks

“Our third-quarter results reflect a continued challenging operating environment, driven by pressure on household budgets, evolving consumer behavior and heightened promotional activity, as well as areas where we need to move faster with focused execution.”

Ryals McMullian, chairman and CEO of Flowers Foods

“While it will take time for our initiatives to translate more fully into results, we believe they are putting Flowers on a stronger path forward. We expect the environment to remain challenging in the near term, but we remain confident in the long-term potential of the business.”

Ryals McMullian, chairman and CEO of Flowers Foods
4:16 PM ET 8-K
Financial Results BlossomHill Therapeutics, Inc. BLSM

BlossomHill Therapeutics Financial Results

BlossomHill Therapeutics reported third quarter 2026 financial results, ending the period with $224.9 million in cash and cash equivalents. The company aligned with the FDA on a Phase 2 dose for BH-30643 and plans to initiate the pivotal SOLARA-2 trial in Q1 2027 for patients with EGFR C797S-positive NSCLC.

Term
Q3 2026

“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI.”

J. Jean Cui, Ph.D., Founder, President and Chief Executive Officer
4:16 PM ET 8-K
Financial Results Azitra, Inc. AZTR

Azitra Financial Results

Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.

Term
Q3 2026

“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”

Francisco Salva, Chief Executive Officer

“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”

Francisco Salva, Chief Executive Officer
4:16 PM ET 8-K
Financial Results Crescent Biopharma, Inc. CBIO

Crescent Biopharma Financial Results

Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.

Counterparty
Kelun-Biotech

“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”

Joshua Brumm, chief executive officer of Crescent

“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”

Joshua Brumm, chief executive officer of Crescent
4:15 PM ET 8-K
Financial Results KinderCare Learning Companies, Inc. KLC

KinderCare Learning Companies Financial Results

KinderCare Learning Companies reported third quarter 2026 revenue of $665.3 million, a 1.7% decrease year-over-year, and a net loss of $85.0 million. The results were impacted by lower enrollment at early childhood education centers and $83.4 million in impairment losses related to market capitalization declines and center closures.

“While third-quarter enrollment at KinderCare Learning Centers fell short of our expectations, recent improvements reinforce our confidence in the operational changes we've made.”

Tom Wyatt, Chairman and Chief Executive Officer

“We know families face tough financial choices, and we’re focused on demonstrating the value of KinderCare’s high-quality education and care across all of our brands.”

Tom Wyatt, Chairman and Chief Executive Officer
4:15 PM ET 8-K
Financial Results Horizon Kinetics Holding Corp HKHC

Horizon Kinetics Holding Financial Results

Horizon Kinetics Holding Corp reported Q3 2026 financial results, including a net loss of $18.4 million primarily driven by unrealized declines in the fair value of key investment holdings. Despite the quarterly loss, year-to-date net income remains positive at $35.8 million, and the company's Board authorized a new $25 million share repurchase program and declared a $0.13 per share dividend.

Term
Q3 2026
4:15 PM ET 10-Q
Financial Results Rekor Systems, Inc. REKR ▶ Call

Rekor Systems Q3 2026 Results: Net Loss of $2.86M, Loss Narrows

Rekor Systems, Inc. reported a decrease in revenue to $10.9 million for the quarter ended September 30, 2026, compared to $14.2 million in the prior year. Despite the revenue decline, the company significantly reduced its net loss to $2.9 million for the quarter, aided by a $3.9 million gain on lease remeasurement and lower overall operating expenses.

Key figure
Net loss $2.86M
4:15 PM ET 10-Q
Financial Results Intellicheck, Inc. IDN ▶ Call

Intellicheck Q3 2026 Results: Net Income $471K, Up 62.4% YoY

Intellicheck, Inc. reported a net income of $1.77 million for the nine months ended September 30, 2026, a significant improvement from a net loss of $279,000 in the prior year period. Total revenues grew to $17.2 million for the nine-month period, and the company maintained a strong liquidity position with $13.17 million in cash and cash equivalents.

Key figure
Net income $471K · +62.4% YoY
4:15 PM ET 8-K
Financial Results Merlin, Inc. MRLN

Merlin Financial Results

Merlin, Inc. reported Q3 2026 revenue of $3.5 million and GAAP net income of $73.8 million, a significant shift from the prior quarter's loss. The company highlighted new contract wins with USSOCOM and USAFRICOM and stated its 2027 plan aims to reduce operating expenses to extend its cash runway into 2029.

Term
Q3 2026

“The new $8.9 million task order with USSOCOM moves our C-130J autonomy program into its integration phase, laying the groundwork for future flight demonstrations and production revenue with SOCOM and ultimately the global C-130J fleet including hundreds of aircraft.”

Matt George, CEO of Merlin

“the goal of our planning process is to ensure that we not only meet the opportunities presented by our current contracts, but also the broader market potential we detailed on last quarter’s call. We believe that it is imperative for Merlin to continue to advance the Merlin Pilot, but it is also imperative that we demonstrate discipline in the investments we make along the way.”

Matt George, CEO of Merlin
4:15 PM ET 10-Q
Financial Results Lgam Private Credit LLC

Lgam Private Credit Q3 2026 Results: Net Income $3.05M, Down 18.2% YoY

LGAM Private Credit LLC reported total investment income of $12.3 million for the quarter ended September 30, 2026, and net investment income of $5.4 million. The company's net asset value per unit decreased to $19.35 from $19.93 at the end of 2025, primarily driven by $6.5 million in net unrealized depreciation on investments during the first nine months of the year.

Key figure
Net income $3.05M · -18.2% YoY
4:15 PM ET 10-Q
Financial Results U S Global Investors Inc GROW

U S Global Investors Q1 2026 Results: Net Income $171K, Down 88.7% YoY

U.S. Global Investors reported net income of $171,000 for the quarter ended September 30, 2026, a significant decrease from $1.5 million in the prior year period, primarily due to lower net investment income. Operating revenues increased to $2.66 million from $2.25 million, while the company maintained a strong cash position of $25.3 million.

Key figure
Net income $171K · -88.7% YoY
4:14 PM ET 10-Q
Financial Results Azitra, Inc. AZTR

Azitra Q3 2026 Results: Net Loss of $2.95M, Loss Widens

Azitra, Inc. reported a net loss of $10.2 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year period. The company significantly strengthened its cash position to $3.8 million through a $10.4 million private placement and warrant exercises, while continuing to invest heavily in research and development for its synthetic biology dermatology platform.

Key figure
Net loss $2.95M
4:14 PM ET 10-Q
Financial Results Merlin, Inc. MRLN

Merlin Q3 2026 Results: Turns Profitable, Net Income $73.8M

Merlin, Inc. reported a significant increase in revenue to $3.46 million for the quarter ended September 30, 2026, and achieved a net income of $73.8 million, primarily driven by a $103.6 million gain from the change in fair value of warrant liabilities. Despite the quarterly profit, the company maintains an accumulated deficit of $626.1 million and recorded a net loss of $75.0 million for the nine-month period.

Key figure
Net income $73.8M
4:14 PM ET 10-Q
Financial Results Audax Credit BDC Inc.

Audax Credit BDC Q3 2026 Results: Net Income $6.75M, Up 13.5% YoY

Audax Credit BDC Inc. reported a net increase in net assets resulting from operations of $13.2 million for the nine months ended September 30, 2026, down from $19.7 million in the prior year period. The decrease was primarily driven by higher net realized and unrealized losses on investments totaling $9.7 million and a decline in total investment income to $27.1 million.

Key figure
Net income $6.75M · +13.5% YoY
4:14 PM ET 8-K
Financial Results Transact Technologies Inc TACT

Transact Technologies Financial Results

TransAct Technologies reported preliminary Q3 2026 financial results with net sales of $14.4 million, up 10% year-over-year, driven by a 33% increase in food service technology revenue. The company reported a net loss of $0.44 million and revised its full-year 2026 revenue guidance downward to $55-$56 million due to softening demand in the Casino and Gaming segment.

Term
Q3 2026

“Our food service technology business drove a strong third quarter, with FST revenue up 33% year-over-year with growth across hardware, software and labels. We sold 2,346 BOHA! units in the quarter, and software revenue grew approximately 61% as pricing actions, new account wins and bundled software packages take hold across our installed base.”

John Dillon, Chief Executive Officer of TransAct

“Casino and Gaming softened in the quarter, consistent with the cyclicality that we have seen in the past, and we expect the softer demand environment to continue into the fourth quarter. However, the fundamentals of this business are unchanged.”

John Dillon, Chief Executive Officer of TransAct
4:14 PM ET 10-Q
Financial Results Antares Strategic Credit Fund II LLC

Antares Strategic Credit Fund II Q3 2026 Results: Net Income $1.87M, Up 47.5% YoY

For the nine months ended September 30, 2026, Antares Strategic Credit Fund II LLC reported total investment income of $11.0 million and net investment income of $5.3 million. The fund's net asset value per share decreased to $24.76 from $25.28 at the end of 2025, primarily due to net unrealized depreciation on investments and distributions declared.

Key figure
Net income $1.87M · +47.5% YoY
4:14 PM ET 10-Q
Financial Results Arcadia Biosciences, Inc. RKDA

Arcadia Biosciences Q3 2026 Results: Net Income $1.75M, Up 105.0% YoY

Arcadia Biosciences reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to a $1.0 million loss in the prior year, primarily driven by valuation losses on financing activities. Total revenues increased to $4.16 million for the nine-month period, while the company strengthened its cash position to $2.84 million through various inducement offers and PIPE financing.

Key figure
Net income $1.75M · +105.0% YoY
4:14 PM ET 10-Q
Financial Results Obsidian Therapeutics, Inc. OBX

Obsidian Therapeutics Q3 2026 Results: Net Loss of $50.7M, Loss Widens

Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.

Key figure
Net loss $50.7M
4:13 PM ET 8-K
Financial Results Serina Therapeutics, Inc. SER

Serina Therapeutics Financial Results

Serina Therapeutics reported third quarter 2026 financial results and provided a clinical update on its SER-252 program for Parkinson's disease. The company has advanced to Cohort 2 of its registrational study following a positive safety review, with topline single-ascending-dose data expected in the first half of 2027.

“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”

Steve Ledger, Chief Executive Officer
4:13 PM ET 8-K
Financial Results Soundthinking, Inc. SSTI

Soundthinking Financial Results

SoundThinking reported third quarter 2026 financial results with revenue of $25.0 million, which remained flat year-over-year. The company reported a GAAP net loss of $8.5 million, widened from a $2.0 million loss in the prior year, largely due to costs associated with its pending acquisition by Transom Capital Group. The company expects to close the Transom Transaction, which values the company at up to $159 million including contingent value rights, in the fourth quarter of 2026.

Term
Q3 2026
4:13 PM ET 10-Q
Financial Results Planet 13 Holdings Inc. PLNH

Planet 13 Holdings Q3 2026 Results: Net Loss of $6.36M, Loss Narrows

Planet 13 Holdings reported a net loss of $20.0 million for the nine months ended September 30, 2026, an improvement from the $59.3 million loss in the prior year period. The company successfully exited all California operations during the quarter and is monitoring the impact of the U.S. Department of Justice's move to reclassify medical marijuana to Schedule III, which may alleviate Section 280E tax burdens.

Key figure
Net loss $6.36M
4:13 PM ET 10-Q
Financial Results Heartflow, Inc. HTFL

Heartflow Q3 2026 Results: Net Loss of $11.5M, Loss Narrows

Heartflow, Inc. reported a total asset base of $355.3 million as of September 30, 2026, with a significant accumulated deficit of $1.14 billion. The company remains focused on its Heartflow FFRCT and Plaque Analysis products while maintaining a liquid position of approximately $167.7 million in cash and short-term investments.

Key figure
Net loss $11.5M
4:13 PM ET 10-Q
Financial Results Serina Therapeutics, Inc. SER

Serina Therapeutics Q3 2026 Results: Net Loss of $7.91M, Loss Widens

Serina Therapeutics reported a net loss of $21.2 million for the nine months ended September 30, 2026, as it continues to invest in research and development. The company significantly strengthened its balance sheet during the period, increasing cash and cash equivalents to $19.4 million through private placements and equity facilities.

Key figure
Net loss $7.91M
4:13 PM ET 10-Q
Financial Results Antares Private Credit Fund

Antares Private Credit Fund Q3 2026 Results: Net Income $21.6M, Up 21.3% YoY

For the nine months ended September 30, 2026, Antares Private Credit Fund reported total investment income of $114.9 million and net investment income of $52.7 million. Net assets increased by $39.5 million from operations, though the fund experienced a net change in unrealized depreciation of $12.0 million during the period.

Key figure
Net income $21.6M · +21.3% YoY
4:12 PM ET 8-K
Financial Results Once Upon a Farm, PBC OFRM

Once Upon a Farm, PBC Financial Results

Once Upon a Farm reported Q3 2026 net sales of $89.1 million, a 35% increase year-over-year driven by 32% volume growth. The company narrowed its net loss to $3.8 million from $11.3 million in the prior year, though Adjusted EBITDA shifted to a $1.0 million loss due to lower gross margins from trade investments and product mix.

Term
Q3 2026

“Third quarter results demonstrated our ability to increase brand awareness and household penetration, deepen and expand retail reach, and deliver value added innovation. As more families consume our products in greater frequency, alongside disciplined investment and execution, we are on course to build the first truly baby through kid brand, with meaningful operating leverage and structurally higher margins as we scale.”

John Foraker, CEO and co-founder of Once Upon a Farm

“We are building one of the most compelling, durable growth platforms in food with increasing household penetration, strong consumer loyalty, attractive retail productivity, and significant opportunities to expand our reach in new categories relevant to our consumers.”

John Foraker, CEO and co-founder of Once Upon a Farm
4:12 PM ET 8-K
Financial Results Sensus Healthcare, Inc. SRTS

Sensus Healthcare Financial Results

Sensus Healthcare reported Q3 2026 revenue of $6.0 million, a 13% decrease year-over-year due to a shift in product mix and the absence of sales to a historically large customer. Despite lower revenue, gross margin improved significantly to 55% from 39.1% in the prior year, and the company reached a milestone of 1,000 SRT systems placed.

Term
Q3 2026

“Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability.”

Joseph Sardano, Chairman and Chief Executive Officer

“Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business.”

Joseph Sardano, Chairman and Chief Executive Officer
4:12 PM ET 10-Q
Financial Results Kodiak Sciences Inc. KOD

Kodiak Sciences Q3 2026 Results: Net Loss of $66.2M, Loss Widens

Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.

Key figure
Net loss $66.2M
4:12 PM ET 10-Q
Financial Results Streamex Corp. STEX

Streamex Q3 2026 Results: Net Loss of $17.5M, Loss Widens

Streamex Corp. reported a significant increase in net loss to $78.7 million for the nine months ended September 30, 2026, compared to $38.8 million in the prior year, primarily driven by a surge in general and administrative expenses. The company transitioned its focus toward gold-leasing activities and digital assets, while successfully extinguishing $38 million in convertible debentures during the period.

Key figure
Net loss $17.5M
4:12 PM ET 10-Q
Financial Results GrabAGun Digital Holdings Inc. PEW ▶ Call

GrabAGun Digital Holdings Q3 2026 Results: Net Loss of $3.05M, Loss Narrows

GrabAGun Digital Holdings Inc. reported a net loss of $6.69 million for the nine months ended September 30, 2026, compared to a loss of $2.92 million in the prior year period, despite a 5.3% increase in net revenues to $70.38 million. The company's cash position decreased to $96.03 million from $110.40 million at year-end 2025, primarily due to increased capital expenditures and stock repurchases.

Key figure
Net loss $3.05M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.